Journal article
Formulary Drug Review: Naldemedine
Hospital pharmacy (Philadelphia), Vol.52(7), pp.464-468
07/2017
Handle:
https://hdl.handle.net/2376/112185
PMCID: PMC5735716
PMID: 29276274
Abstract
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary,
Hospital Pharmacy
publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The September 2017 monograph topics are brigatinib, durvalumab, edaravone, midostaurin, and sarilumab. The MUE is on sarilumab.
Metrics
10 Record Views
Details
- Title
- Formulary Drug Review: Naldemedine
- Creators
- Danial E Baker - Washington State University, Spokane, USA
- Publication Details
- Hospital pharmacy (Philadelphia), Vol.52(7), pp.464-468
- Academic Unit
- Pharmacotherapy, Department of
- Publisher
- SAGE Publications; Sage CA: Los Angeles, CA
- Identifiers
- 99900547685901842
- Language
- English
- Resource Type
- Journal article